Overregulation of conflicts hinders medical progress

Thomas P. Stossel, MD
Professor of Medicine, Harvard Medical School, Boston, MA

Correspondence: Thomas P. Stossel, MD, Professor of Medicine, Harvard Medical School, Brigham and Women’s Hospital, 1 Blackfan Circle, Karp 6, Boston, MA 02115; [email protected]

Dr. Stossel reported that he has ownership interests in ZymeQuest, Inc., and in Critical Biologics Corp.; has intellectual property rights in Critical Biologics Corp.; has received consulting/advisory fees from Merck, Inc.; has received honoraria from Pfizer, Inc.; and has received royalties from Lippincott Williams & Wilkins.

Thomas P. Stossel, MD
Professor of Medicine, Harvard Medical School, Boston, MA

Correspondence: Thomas P. Stossel, MD, Professor of Medicine, Harvard Medical School, Brigham and Women’s Hospital, 1 Blackfan Circle, Karp 6, Boston, MA 02115; [email protected]

Dr. Stossel reported that he has ownership interests in ZymeQuest, Inc., and in Critical Biologics Corp.; has intellectual property rights in Critical Biologics Corp.; has received consulting/advisory fees from Merck, Inc.; has received honoraria from Pfizer, Inc.; and has received royalties from Lippincott Williams & Wilkins.

Thomas P. Stossel, MD
Professor of Medicine, Harvard Medical School, Boston, MA

Correspondence: Thomas P. Stossel, MD, Professor of Medicine, Harvard Medical School, Brigham and Women’s Hospital, 1 Blackfan Circle, Karp 6, Boston, MA 02115; [email protected]

Dr. Stossel reported that he has ownership interests in ZymeQuest, Inc., and in Critical Biologics Corp.; has intellectual property rights in Critical Biologics Corp.; has received consulting/advisory fees from Merck, Inc.; has received honoraria from Pfizer, Inc.; and has received royalties from Lippincott Williams & Wilkins.